Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 1.00 |
| ▸ | PRKCB | P05771 | 15/20 | 1.00 |
| ▸ | PRKCA | P17252 | 14/20 | 1.00 |
| ▸ | PRKCG | P05129 | 14/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 7/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 6/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 0.69 |
| ▸ | CDK1 | P06493 | 2/20 | 0.69 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.69 |
| ▸ | PRKCH | P24723 | 2/20 | 0.64 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.64 |
| ▸ | CDK4 | P11802 | 1/20 | 0.64 |
| ▸ | CCND1 | P24385 | 1/20 | 0.64 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.64 |
| ▸ | CAMK2B | Q13554 | 2/20 | 0.62 |
| ▸ | CAMK2G | Q13555 | 2/20 | 0.62 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.62 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.62 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.62 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4343058 | 1.00 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGPRKCE | |
| SCHEMBL14522451 | 0.92 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGPRKCE | |
| SCHEMBL4336077 | 0.91 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGPRKCE | |
| SCHEMBL4344559 | 0.88 | GSK3B (1.00) | GSK3BPRKCBPRKCAPRKCGPRKCE | |
| SCHEMBL14522441 | 0.85 | GSK3B (0.85) | GSK3BPRKCBPRKCAPRKCGPRKCE | |
| SCHEMBL30336889 | 0.85 | PRKCB (0.74) | GSK3BPRKCBPRKCAPRKCGPRKCE | |
| SCHEMBL30336971 | 0.85 | PRKCB (0.74) | GSK3BPRKCBPRKCAPRKCGPRKCE | |
| SCHEMBL12629162 | 0.85 | PRKCB (0.74) | GSK3BPRKCBPRKCAPRKCGPRKCE | |
| SCHEMBL22765422 | 0.85 | PRKCB (0.74) | GSK3BPRKCBPRKCAPRKCGPRKCE | |
| SCHEMBL29800011 | 0.85 | PRKCB (0.74) | GSK3BPRKCBPRKCAPRKCGPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. (US) | 2018-05-10 | — | — | US | disclosed |
| EP-2664669-B1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH INC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9845460-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20140080210-A1 | Treatment of Pluripotent Cells | JANSSEN BIOTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8623648-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2664669-A1 | Treatment of pluripotent cells | Janssen Biotech, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20090325293-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. | 2009-12-31 | — | — | US | disclosed |
| EP-1345946-B1 | MACROHETEROCYLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2005-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127723-A1 | TREATMENT OF PLURIPOTENT CELLS | GSK3B, GSK3A, GSKIP | GSK3B 1/4885PRKCB 61/4885PRKCA 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.